

# BCCA Protocol Summary for Palliative Therapy for Advanced Breast Cancer Using Exemestane

**Protocol Code:** BRAVEXE  
**Tumour Group:** Breast  
**Contact Physician:** Dr. Susan Ellard

## ELIGIBILITY:

- hormonal treatment for hormone receptor positive advanced breast cancer in postmenopausal women
- consideration should first be given to using BRAVEVEX for fit patients after recurrence or progression on a non-steroidal aromatase inhibitor (anastrozole or letrozole).

## EXCLUSION CRITERIA:

- Premenopausal women.

## TESTS:

- None required.

## TREATMENT:

- Exemestane 25 mg po daily until evidence of progression.

**Contact Dr. Susan Ellard or tumour group delegate at (250) 712-3900 or 1-888-563-7773 with any problems or questions regarding this treatment program.**

Date Activated: 01 July 2001

Date Revised: 01 May 2014 (Minor typo corrected)

## REFERENCES:

1. Kaufmann M, Bajetta E, Dirix LY et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol 2000;18:1399-411.
2. Lonning PE, Bajetta E, Murray R et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 2000;18:2234-44.